awmsg logo



brentuximab vedotin (Adcetris®)


Reference No. 1693

Excluded date:
12/01/2018


Appraisal information

brentuximab vedotin (Adcetris®) powder for solution for infusion


Company: Takeda UK Ltd
BNF category: Malignant disease and immunosupression
   
   
Submission Type: Unspecified
Status: Excluded

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least 1 prior systemic therapy

AWMSG advice

Product meets AWMSG exclusion criteria due to NICE appraisal